Light Needle for Opioid Use Disorder
NCT05341219 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100
Last updated 2023-05-03
Summary
This randomized-controlled study investigates the effect of adjuvant light needle in the treatment of heroin addicts. One hundred heroin addicts older than 20 years old enrolled from the Addiction Treatment Center at Kaohsiung Chang Gung Memorial Hospital and Department of Psychiatry at Kaohsiung Medical University Hospital are randomly allocated to experimental or control group. Subjects in experimental group are treated with light needle on the wrist pulse (Cunkou) 12 times within 4 weeks. Subjects in the control group received a sham light needle treatment, without any laser output. Outcome measurements include check of urine morphine, report of the subjects' times or days of heroin use, self-filling Visual Analogue Scales of heroin craving / refusal of heroin use (0-10 points) during last week, report of the subjects' quality of life using Short Form-12v2, and record of the subject's pulse diagnosis and heart rate variability before and after treatment.
Conditions
Interventions
- PROCEDURE
-
Light needle therapy
The study participants will receive 12 sessions of light needle therapy within 4 weeks using a gallium aluminum arsenide Physiolaser olympic (maximal power, 60mW; wavelength, 655 nm; area of probe, 0.008 cm2; power density, 7.5 W/cm2; pulsed-wave; RJ-Laser, Reimers \& Janssen GmbH, Waldkirch, Germany). Those in the experimental group received a total 135 J of energy delivered from 6 light needles being placed between LU7 and LU9. The light needle therapy was applied to each point for 15 min.
- PROCEDURE
-
Sham light needle therapy
The study participants will receive 12 sessions of sham light needle therapy, without any laser output (no stimulation), within 4 weeks using a gallium aluminum arsenide Physiolaser olympic. Those in the control group received 0 J of energy delivered from 6 light needles being placed between LU7 and LU9 for 15 min.
Sponsors & Collaborators
-
Kaohsiung Medical University
collaborator OTHER -
Chang Gung Memorial Hospital
lead OTHER
Principal Investigators
-
Wen-Long Hu, MD, MS · Chief, Division of Acupuncture, Kaohsiung Chang Gung Memorial Hospital
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 20 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-03-18
- Primary Completion
- 2024-02-14
- Completion
- 2024-02-14
Countries
- Taiwan
Study Locations
More Related Trials
-
Pharmacodynamic Evaluation of Intranasal Nalmefene
NCT04828005 ·Status: COMPLETED ·Phase: PHASE1
-
A Usability Assessment of Naloxone by Community Members
NCT03309449 ·Status: COMPLETED ·Phase: NA
-
Increasing Patient Knowledge of the Signs of Opioid Overdose and Naloxone in a Suburban Treatment Program
NCT02120612 ·Status: COMPLETED
-
Low-dose Buprenorphine Initiation for Opioid Use Disorder
NCT05450718 ·Status: RECRUITING ·Phase: PHASE4
-
Pilot Research on Opioid Use Disorder
NCT04244227 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Efficacy And Safety Of An Innovative Treatment Of Opiate Use Disorders
NCT04340622 ·Status: COMPLETED ·Phase: NA
-
Effects of Buprenorphine and Naloxone in Opiate Addicts - 4
NCT00000355 ·Status: COMPLETED ·Phase: PHASE1
-
The Acupuncture for Pain, Opioid Use Disorder and Mood
NCT06543355 ·Status: COMPLETED ·Phase: NA
-
Effect of Buprenorphine/Naloxone Continuation on Pain Control and Opioid Use
NCT03266445 ·Status: UNKNOWN ·Phase: PHASE4
-
Transdermal Electroacupuncture for Opioid Detoxification
NCT00742170 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-3 - 6
NCT00000331 ·Status: WITHDRAWN ·Phase: PHASE2
-
Evaluation of Intranasal Naltrexone and Naloxone
NCT03851731 ·Status: COMPLETED ·Phase: PHASE1
-
Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-1 - 4
NCT00000329 ·Status: WITHDRAWN ·Phase: PHASE2
-
Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2 - 5
NCT00000330 ·Status: WITHDRAWN ·Phase: PHASE2
-
Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment III) - 3
NCT00000328 ·Status: WITHDRAWN ·Phase: PHASE2
-
Comparing Rapid Micro-Induction and Standard Induction of Buprenorphine/Naloxone for Treatment of Opioid Use Disorder
NCT04234191 ·Status: RECRUITING ·Phase: PHASE2
-
Evaluating Tetrahydrocannabinol as an Adjunct to Opioid Agonist Therapy
NCT05985850 ·Status: RECRUITING ·Phase: PHASE2
-
A Project to Test the Efficacy and Safety of An Innovative Treatment for Opiate Use Disorders.
NCT05995873 ·Status: UNKNOWN ·Phase: NA
-
SOONER Feasibility Study Protocol
NCT03821649 ·Status: COMPLETED ·Phase: NA
-
Addition of Naltrexone to Methadone Taper
NCT00135759 ·Status: COMPLETED ·Phase: PHASE2
-
The Impact of Co-Dispensing Naloxone to Patients Prescribed Chronic Opioid Therapy
NCT03337100 ·Status: COMPLETED ·Phase: NA
-
Increasing Naloxone Access for Persons Who Use Opioids
NCT04303000 ·Status: COMPLETED ·Phase: PHASE4
-
Combined tDCS and Cognitive Training as an Adjunctive Treatment in Opioid Use Disorder
NCT07158853 ·Status: RECRUITING ·Phase: NA
-
Low-dose Versus a High-dose Sublingual Buprenorphine Induction
NCT05944952 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Blood Naloxone Levels Following Intradermal Injection in Humans
NCT05876572 ·Status: WITHDRAWN ·Phase: PHASE4